Overcoming Resistance to CDK4/6 Inhibitors
The standard treatment for ER-positive, HER2-negative MBC is a combination of hormone therapy plus a CDK4/6 inhibitor: palbociclib (Ibrance®), ribociclib...
Read More PAST ARTICLES
2023
2021
- Metastatic Breast Cancer News from 2021 ESMO
- Metastatic Breast Cancer News from ASCO 2021
- Update on Oral SERDs for Estrogen Receptor-Positive MBC
- MBC News from 2021 AACR Meeting
- St. Gallen International Breast Cancer Conference 2021
- The Latest Research on Hormone Receptor-Positive (HR+) MBC
- What is Next-Generation Sequencing?
- Lines of Therapy: New Drugs May Change MBC Treatment
SEARCH OUR SITE
for past articles or specific information.